RxDoctor Payments Data

Jonathon Hennings

Nurse Practitioner · Waterloo, IANPI 1376777383

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (37.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Radius Health, Inc. at 50.5% of the total. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,357in general payments, 2019–2025

Across 132 payments — averaging $86.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$6K
  • AstraZeneca$5K
  • Amgen$447
  • Kyowa Kirin, Inc.$108
  • Lilly USA, LLC$90
  • Boehringer Ingelheim$82
  • plus $358 from 13 others

What the payments were for

  • Consulting fees$1,99018%
  • Speaking & faculty fees$4,29038%
  • Travel & lodging$2,64123%
  • Food & beverage$2,42721%
  • Education$90%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,357 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$707,813
Medicare patients
555
Services billed
31,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StrensiqAsfotase Alfa82$7,853,892
TymlosAbaloparatide79$226,699
Teriparatide30$71,696
ForteoTeriparatide12$52,197
Alendronate Sodium162$1,224
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic21$1,173
Raloxifene Hcl26$1,138
Fluticasone Propionate21$179
Prednisone15$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaStrensiq$4,539$7,853,89282 claims
Radius Health, Inc.Tymlos$5,733$226,69979 claims
Lilly USA, LLCForteo$90$52,19712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →